Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (Nasdaq: PHIO) recently announced promising results from studies of its INTASYL™ compounds at the 37th Annual Meeting of the Society for Immunotherapy of Cancer. These compounds target multiple proteins, showing preclinical activity in Direct-to-Tumor and Adoptive Cell Therapy applications. Notable compounds included PH-762, PH-894, and PH-109, all of which demonstrated significant potential in enhancing T cell activity against tumor cells. The company expects to report topline safety data for PH-762 in early Q1 2023.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston from November 8-12, 2022. The company will present updates on its programs, including first-in-human clinical trial data for PH-762 in advanced melanoma. Key highlights include collaborations with AgonOx, Inc. to enhance tumor infiltrating lymphocytes and preclinical data on targets for cancer immunotherapy using INTASYL™ compounds. Details of the presentations will be made available on the company's website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the appointment of Robert Bitterman as interim Executive Chairman of the Board, taking on roles of principal executive officer and principal financial officer. Bitterman, with 25 years in the pharmaceutical sector, has been a board director since 2012. The company also appointed Robert Ferrara as Lead Independent Director, who has board experience since 2019 and extensive financial expertise. These leadership changes aim to enhance operational oversight and strategic direction.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced preclinical data at the 9th Immunotherapy of Cancer Conference showing that its lead product, PH-762, enhances T cell populations with stem cell-like characteristics. This improvement is expected to increase T cell persistence in vivo, thereby enhancing anti-tumor activity. The study indicates that PH-762 could downregulate PD-1, a target in immunotherapy, allowing T cells to kill cancer cells more effectively. A first-in-human clinical trial of PH-762 for advanced melanoma is currently underway.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the acceptance of six abstracts for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-12, 2022, in Boston, MA. The abstracts will cover in vitro and in vivo tumor efficacy and clinical work on INTASYL compounds targeting various immune checkpoints. The company aims to advance its immuno-oncology efforts using its self-delivering RNAi therapeutic platform, particularly focusing on the PD-1 gene silencing compound PH-762.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the initiation of a first-in-human clinical trial for PH-762 targeting advanced melanoma, with top-line data expected in Q1 2023. The company plans to begin a clinical trial for PH-762 combined with double positive tumor infiltrating lymphocytes by Q4 2022 in collaboration with AgonOx. Financial results revealed a 16% decrease in R&D expenses to $1.3 million, contributing to a 6% reduction in net loss to $2.5 million. Despite cash reserves dropping to $18 million, the company expects to fund operations through Q4 2023.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) presented a trial-in-progress poster detailing its Phase 1b clinical trial of PH-762, a self-delivering RNAi targeting PD-1, for advanced melanoma at the 2022 ASCO annual meeting. The study evaluates the safety, pharmacokinetics, and potential tumor responses of neoadjuvant use of PH-762 via intratumoral injection. With ongoing trials at Gustave Roussy Institute, the company aims to fill the gap in neoadjuvant treatments for this patient group. Initial results suggest a robust inhibition of tumor growth and minimal systemic side effects, marking progress in immunotherapy options.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data on May 16, 2022, demonstrating that its self-delivering RNAi compound, PH-894, can enhance CAR-T cell products by silencing BRD4 during the activation and expansion phases. This improvement could address challenges such as cell exhaustion, increasing the effectiveness of CAR-T therapies for solid tumors. The data will be presented at the ASGCT Annual Meeting in Washington D.C. from May 16-19, 2022.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has opened enrollment for its first-in-human clinical trial of PH-762, aimed at treating advanced melanoma. The study will assess safety and anti-tumor activity, with initial data expected in Q1 2023. Phio is also finalizing IND-enabling studies for PH-894, targeting patients unresponsive to PD-1 therapy. For Q1 2022, the company reported a net loss of $2.6 million, down from $3.4 million in Q1 2021, due to reduced R&D expenses. Cash reserves stand at $20.5 million, sufficient to fund operations into Q2 2023.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the departure of Dr. Gerrit Dispersyn as President and CEO effective May 5, 2022. Dispersyn, who joined in 2017, played a key role in transitioning the company towards immuno-oncology therapeutics, particularly through the INTASYL™ platform targeting cutaneous melanoma. Following his departure, Dr. Geert Cauwenbergh, the former CEO, will serve as Principal Executive Officer until a new CEO is appointed. This leadership change comes as the company progresses in developing its RNAi therapeutic platform.